Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir

Mayanna Habktéo; Ali Mahamat Moussa; Djerabet Franckly; Eiba Tamam; Tahir Mahamat Saleh; Mairé Dehainssala

doi:doi:10.11648/j.ijcems.20230902.12

| Peer-Reviewed

Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir

Mayanna Habktéo, Ali Mahamat Moussa, Djerabet Franckly, Eiba Tamam, Tahir Mahamat Saleh, Mairé Dehainssala

Published in International Journal of Clinical and Experimental Medical Sciences (Volume 9, Issue 2)

Received: 20 March 2023 Accepted: 10 April 2023 Published: 10 May 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.

Published in	International Journal of Clinical and Experimental Medical Sciences (Volume 9, Issue 2)
DOI	10.11648/j.ijcems.20230902.12
Page(s)	25-28
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Chronic Hepatitis B, Tenofovir, HBV-DNA, Transaminases, Patients, Chad

References

[1]	World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017 [Internet]. Geneva, Switzerland: World Health Organization; 2017.
[2]	Paccoud O, Surgers L, Lacombe K. Infection par le virus de l’Hépatite B: histoire naturelle, manifestations cliniques et principes thérapeutiques. Revue de médecine interne. [Hepatitis B virus infection: natural history, clinical manifestations and therapeutic principles. Journal of Internal Medicine.]. 2019; 40: 590-98.
[3]	Rapport sur l’Hépatite B et C au Canada: 2018 [Report on Hepatitis B and C in Canada: 2018].
[4]	Lahlali M, Abid H, Lamine A, Lahmidani N, El Yousfi M, Benajah D et al. Epidémiologie des hépatites virales dans le Grand Maghreb. La Tunisie Médicale. [Epidemiology of viral hepatitis in the Greater Maghreb. Medical Tunisia]. 2018; 96 (10-11): 606-19.
[5]	Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBs Ag seroprevalence and endemicity. Vaccine. 2012; 30 (12): 2212–19.
[6]	Salamata D, Marie LB, Mamadou NG, Mame AT, Daouda D, Mouhamadou M et al. Hépatite virale B: aspects cliniques, paracliniques et évolutifs dans le service d’Hépato Gastroentérologie de l’Hôpital Aristide Le Dantec: à propos de 728 cas. [Viral hepatitis B: clinical, paraclinical and evolutionary aspects in the Hepato Gastroenterology department of the Aristide Le Dantec Hospital: about 728 cases]. Pan African Medical Journal. 2018; 31: 1-7.
[7]	Katilé D, Konaté I, Goita D, Kaboré M, Dicko MY, Mallé O, et al. Prevalence of HBs Antigen and serological profile of Hepatitis B virus in General Medicine Consultation at the Regional Hospital of Kayes in Mali. Health Sci. Dis. October - November - December 2018; Vol 19 (4): 16-19.
[8]	Bessimbaye N, Moussa AM, Mbanga D, Tidjani A, Mahamat SO, Nahor Ngawara M et al. Seroprevalence of HBsAg and Anti-HCV antibody in HIV1 infected persons in N'Djaména, Chad. Bull Soc Pathol Exot; (2014) 107: 327-31.
[9]	Moussa AM, Habkreo M, Chatté A, Bordé E, Fouda AA. Nadlaou B. Frequency of Viral Replication Markers in Chronic HBV Carriers in N'Djamena, Chad. Open Journal of Gastroenterology. 2022; 12: 271-77.
[10]	Touré PS, Berthé A, Diop MM, Diarra AS, Lo G, Sow-Sall A, et al. Non-invasive markers in the evaluation of liver fibrosis in Senegalese chronic hepatitis B virus carriers: about 404 cases. RAFMI 2017; 4 (2): 30-34.
[11]	Gueye MN, Sarr B, Diallo S, Diouf G, Daouda D, Thioubou MA, et al. Assessment of the state of knowledge on viral hepatitis B of patients in Hepato-Gastroenterology consultation at the General Idrissa Pouye Hospital. OSR Journal of Dental and Medical Sciences. 2020 Jun, 19: 53-57.
[12]	Guangqin X, Jiayin Y, Lunan Y. Comparison of Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Adult Patients with Chronic Hepatitis B Virus Infection: A Systemic Review and Meta-analysis, American Association for the Study of Liver Diseases. 24 Nov 2014, 61 (1): 292-302.
[13]	INSEED. Enquête Démographique et de sante et à indicateurs Multiples au Tchad (EDS-MICS). [Demographic and Health Survey and Multiple Indicators in Chad (EDS-MICS)]. 2014-2015. 2016.
[14]	Jerome G and the working group. "Biological markers of hepatic fibrosis. Non-invasive assessment of liver fibrosis during chronic viral hepatitis C. Presse Med. 2006; 35: 1317-26.
[15]	World Health Organization. Guidelines for prevention, care and treatment for people with chronic hepatitis B infection April 2016.
[16]	Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.
[17]	Sombié R, Sangaré L, Guingané A, Tiendrébéogo A, Kaboré D, Bougouma A. Treatment of chronic hepatitis B with nucleos(t)ides analogues. J Afr Hepato-Gastroenterology. sept 2015; 9 (3): 114-8.
[18]	Sombié R, Bougouma A, Diallo O, Bonkoungou G, Cissé R, Sangare L et al. Chronic hepatitis B: epidemiological, diagnostic, therapeutic, and evolutionary aspects at the Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou. J Afr Hepato Gastroenterology. Jan 2010; 4 (1): 3-10.

Cite This Article

Plain Text BibTeX RIS

APA Style

Mayanna Habktéo, Ali Mahamat Moussa, Djerabet Franckly, Eiba Tamam, Tahir Mahamat Saleh, et al. (2023). Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. International Journal of Clinical and Experimental Medical Sciences, 9(2), 25-28. https://doi.org/10.11648/j.ijcems.20230902.12

Copy | Download

ACS Style

Mayanna Habktéo; Ali Mahamat Moussa; Djerabet Franckly; Eiba Tamam; Tahir Mahamat Saleh, et al. Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. Int. J. Clin. Exp. Med. Sci. 2023, 9(2), 25-28. doi: 10.11648/j.ijcems.20230902.12

Copy | Download

AMA Style

Mayanna Habktéo, Ali Mahamat Moussa, Djerabet Franckly, Eiba Tamam, Tahir Mahamat Saleh, et al. Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. Int J Clin Exp Med Sci. 2023;9(2):25-28. doi: 10.11648/j.ijcems.20230902.12

Copy | Download

@article{10.11648/j.ijcems.20230902.12,
  author = {Mayanna Habktéo and Ali Mahamat Moussa and Djerabet Franckly and Eiba Tamam and Tahir Mahamat Saleh and Mairé Dehainssala},
  title = {Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir},
  journal = {International Journal of Clinical and Experimental Medical Sciences},
  volume = {9},
  number = {2},
  pages = {25-28},
  doi = {10.11648/j.ijcems.20230902.12},
  url = {https://doi.org/10.11648/j.ijcems.20230902.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20230902.12},
  abstract = {Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.},
 year = {2023}
}

Copy | Download

TY - JOUR
T1 - Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir
AU - Mayanna Habktéo
AU - Ali Mahamat Moussa
AU - Djerabet Franckly
AU - Eiba Tamam
AU - Tahir Mahamat Saleh
AU - Mairé Dehainssala
Y1 - 2023/05/10
PY - 2023
N1 - https://doi.org/10.11648/j.ijcems.20230902.12
DO - 10.11648/j.ijcems.20230902.12
T2 - International Journal of Clinical and Experimental Medical Sciences
JF - International Journal of Clinical and Experimental Medical Sciences
JO - International Journal of Clinical and Experimental Medical Sciences
SP - 25
EP - 28
PB - Science Publishing Group
SN - 2469-8032
UR - https://doi.org/10.11648/j.ijcems.20230902.12
AB - Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.
VL - 9
IS - 2
ER -

Copy | Download

Author Information

Mayanna Habktéo

Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad
Ali Mahamat Moussa

Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad
Djerabet Franckly

Department of Medicine of the Chad-China Friendship Hospital, N'Djamena, Chad
Eiba Tamam

Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad
Tahir Mahamat Saleh

Internal Medicine Department of the Centre Hospitalier Universitaire la Renaissance, N'Djamena, Chad
Mairé Dehainssala

Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mayanna Habktéo, Ali Mahamat Moussa, Djerabet Franckly, Eiba Tamam, Tahir Mahamat Saleh, et al. (2023). Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. International Journal of Clinical and Experimental Medical Sciences, 9(2), 25-28. https://doi.org/10.11648/j.ijcems.20230902.12

Copy | Download

ACS Style

Mayanna Habktéo; Ali Mahamat Moussa; Djerabet Franckly; Eiba Tamam; Tahir Mahamat Saleh, et al. Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. Int. J. Clin. Exp. Med. Sci. 2023, 9(2), 25-28. doi: 10.11648/j.ijcems.20230902.12

Copy | Download

AMA Style

Mayanna Habktéo, Ali Mahamat Moussa, Djerabet Franckly, Eiba Tamam, Tahir Mahamat Saleh, et al. Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. Int J Clin Exp Med Sci. 2023;9(2):25-28. doi: 10.11648/j.ijcems.20230902.12

Copy | Download

@article{10.11648/j.ijcems.20230902.12,
  author = {Mayanna Habktéo and Ali Mahamat Moussa and Djerabet Franckly and Eiba Tamam and Tahir Mahamat Saleh and Mairé Dehainssala},
  title = {Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir},
  journal = {International Journal of Clinical and Experimental Medical Sciences},
  volume = {9},
  number = {2},
  pages = {25-28},
  doi = {10.11648/j.ijcems.20230902.12},
  url = {https://doi.org/10.11648/j.ijcems.20230902.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20230902.12},
  abstract = {Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.},
 year = {2023}
}

Copy | Download